Top

Published in:

Open Access 01-12-2021 | Hepatitis C | Research

Hepatitis C virus DNA vaccines: a systematic review

Authors: Ali Shayeghpour, Roya Kianfar, Parastoo Hosseini, Mehdi Ajorloo, Sepehr Aghajanian, Mojtaba Hedayat Yaghoobi, Tayebeh Hashempour, Sayed-Hamidreza Mozhgani

Published in: Virology Journal | Issue 1/2021

Abstract

Background

Vaccination against HCV is an effective measure in reduction of virus-related public health burden and mortality. However, no prophylactic vaccine is available as of yet. DNA-based immunization is a promising modality to generate cellular and humoral immune responses. The objective of this study is to provide a systematic review of HCV DNA vaccines and investigate and discuss the strategies employed to optimize their efficacies.

Methods

MEDLINE (PubMed), Web of Science, Scopus, ScienceDirect, and databases in persian language including the Regional Information Centre for Science & Technology (RICeST), the Scientific Information Database and the Iranian Research Institute for Information Science and Technology (IranDoc) were examined to identify studies pertaining to HCV nucleic acid vaccine development from 2000 to 2020.

Results

Twenty-seven articles were included. Studies related to HCV RNA vaccines were yet to be published. A variety of strategies were identified with the potential to optimize HCV DNA vaccines such as incorporating multiple viral proteins and molecular tags such as HBsAg and Immunoglobulin Fc, multi-epitope expression, co-expression plasmid utilization, recombinant subunit immunogens, heterologous prime-boosting, incorporating NS3 mutants in DNA vaccines, utilization of adjuvants, employment of less explored methods such as Gene Electro Transfer, construction of multi- CTL epitopes, utilizing co/post translational modifications and polycistronic genes, among others. The effectiveness of the aforementioned strategies in boosting immune response and improving vaccine potency was assessed.

Conclusions

The recent progress on HCV vaccine development was examined in this systematic review to identify candidates with most promising prophylactic and therapeutic potential.

Yazdanian M, Memarnejadian A, Mahdavi M, Motevalli F, Sadat SM, Vahabpour R, Khanahmad H, Soleimanjahi H, Budkowska A, Roohvand F. Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice. Adv Biomed Res. 2015;4:13.PubMedPubMedCentralCrossRef

Mohamadi M, Azarbayjani K, Mozhgani S-H, Bamdad T, Alamdary A, Nikoo HR, Hashempour T, Hedayat Yaghoobi M, Ajorloo M. Hepatitis C virus alternative reading frame protein (ARFP): Production, features, and pathogenesis. J Med Virol. 2020;92(12):2930–7.CrossRef

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.PubMedCrossRef

Roingeard P, Beaumont E. Hepatitis C vaccine: 10 good reasons for continuing. Hepatology (Baltimore, MD). 2020;71:1845.CrossRef

Wu J, Zhou Y, Fu X, Deng M, Zheng Y, Tian G, Li Y, Wang C, Ding C, Ruan B. The burden of chronic hepatitis C in China from 2004 to 2050: an individual-based modeling study. Hepatology. 2019;69(4):1442–52.PubMedCrossRef

Ayoub HH, Al Kanaani Z, Abu-Raddad LJ. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan. J Viral Hepatitis. 2018;25(6):670–9.CrossRef

Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1001.PubMedCrossRef

Li D, Huang Z, Zhong J. Hepatitis C virus vaccine development: old challenges and new opportunities. Natl Sci Rev. 2015;2(3):285–95.CrossRef

Bailey JR. Barnes E. Cox ALJG: Approaches, progress, and challenges to hepatitis C vaccine development. 2019;156(2):418–30.

10.

Lindenbach BD. Measuring HCV infectivity produced in cell culture and in vivo. In: Hepatitis C. edn.: Springer; 2009: 329–336.

11.

Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines. 2009;8(3):333–45.PubMedPubMedCentralCrossRef

12.

Pouriayevali MH, Bamdad T, Aghasadeghi MR, Sadat SM, Sabahi F: Construction and immunogenicity analysis of hepatitis C virus (HCV) truncated non-structural protein 3 (NS3) plasmid vaccine. Jundishapur Journal of Microbiology 2016, 9(3).

13.

Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspe G, Fournillier A. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine. 2008;26(20):2471–81.PubMedCrossRef

14.

Dueñas-Carrera S, Alvarez-Lajonchere L, Alvarez-Obregón JC, Pérez A, Acosta-Rivero N, Vázquez DM, Martínez G, Viña A, Pichardo D, Morales J. Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem. 2002;35(3):205–12.PubMedCrossRef

15.

Deng Y, Zhang K, Tan W, Wang Y, Chen H, Wu X, Ruan L. A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice. Vaccine. 2009;27(15):2085–8.PubMedPubMedCentralCrossRef

16.

Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepatitis Month. 2014;14(10):e22215.

17.

Capone S, Zampaglione I, Vitelli A, Pezzanera M, Kierstead L, Burns J, Ruggeri L, Arcuri M, Cappelletti M, Meola A, et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol. 2006;177(10):7462–71.PubMedCrossRef

18.

Encke J, Radunz W, Eisenbach C, Geib J, Gehrke S, Pfaff E, Stremmel W. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection. Eur J Clin Invest. 2007;37(5):396–406.PubMedCrossRef

19.

Levander S, Sallberg M, Ahlen G, Frelin L. A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. Vaccine. 2016;34:2821.PubMedCrossRef

20.

Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther. 2016;23(1):26–37.PubMedCrossRef

21.

Pishraft-Sabet L, Kosinska AD, Rafati S, Bolhassani A, Taheri T, Memarnejadian A, Alavian SM, Roggendorf M, Samimi-Rad K. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96. Adv Virol. 2015;160(1):141–52.

22.

Hartoonian C, Sepehrizadeh Z, Mahdavi M, Arashkia A, Jang YS, Ebtekar M, Yazdi MT, Negahdari B, Nikoo A, Azadmanesh K. Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant. Mol Biol Rep. 2014;41(9):5943–52.PubMedCrossRef

23.

Naderi M, Saeedi A, Moradi A, Kleshadi M, Zolfaghari MR, Gorji A, Ghaemi A. Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virologica Sinica. 2013;28(3):167–73.PubMedPubMedCentralCrossRef

24.

Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, Azadmanesh K. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine. 2009;46(1):43–50.PubMedCrossRef

25.

Frelin L, Alheim M, Chen A, Soderholm J, Rozell B, Barnfield C, Liljestrom P, Sallberg M. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther. 2003;10(8):686–99.PubMedCrossRef

26.

Behzadi MA, Alborzi A, Kalani M, Pouladfar G, Dianatpour M, Ziyaeyan M. Immunization with a recombinant expression vector encoding NS3/NS4A of Hepatitis C virus genotype 3a elicits cell-mediated immune responses in C57BL/6 mice. Viral Immunol. 2016;29(3):138–47.PubMedCrossRef

27.

Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L, Hoglund U, Blomberg P, Fons M, Mathiesen I, Sallberg M. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol (Baltimore, Md: 1950). 2007;179(7):4741–53.CrossRef

28.

Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, Hotta H. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. PLoS ONE. 2014;9(6):e98877.PubMedPubMedCentralCrossRef

29.

Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trepo C, Bain C, Lone YC, Inchauspe G, Fournillier A. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. J Med Virol. 2004;74(3):397–405.PubMedCrossRef

30.

Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology. 2005;42(6):1429–36.PubMedCrossRef

31.

Cao J, Chen Z, Ren Y, Luo Y, Cao M, Lu W, Zhao P, Qi Z. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice. Vaccine. 2011;29(20):3714–23.PubMedCrossRef

32.

Masalova OV, Lesnova EI, Permyakova KY, Ivanov AV, Tunitskaya VL, Kushch AA. Enhancement of the immune response by codelivery of hepatitis C virus recombinant DNA and proteins of the replicative complex. Mol Genet Microbiol Virol. 2015;30(1):39–47.CrossRef

33.

Pancholi P, Liu Q, Tricoche N, Pei Z, Perkus ME, Prince AM. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins. J Infect Dis. 2000;182(1):18–27.PubMedCrossRef

34.

Dawood RM, Moustafa RI, Abdelhafez TH, El-Shenawy R, El-Abd Y, El Din NGB, Dubuisson J. El Awady MKJBid: A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. 2019;19(1):932.

35.

Ghorbani M, Nass T, Azizi A, Soare C, Aucoin S, Giulivi A, Anderson DE, Diaz-Mitoma F. Comparison of antibody- and cell-mediated immune responses after intramuscular hepatitis C immunizations of BALB/c mice. Viral Immunol. 2005;18(4):637–48.PubMedCrossRef

36.

Shi L, Liu S, Fan GX, Sheng L, Ren HX, Yuan YK. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes. Viral Immunol. 2006;19(4):702–11.PubMedCrossRef

37.

Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82(21):10896–905.PubMedPubMedCentralCrossRef

38.

Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 2003;21(15):1629–39.PubMedCrossRef

39.

Estcourt MJ, Ramsay AJ, Brooks A, Thomson SA, Medveckzy CJ, Ramshaw IA. Prime–boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol. 2002;14(1):31–7.PubMedCrossRef

40.

Guan J, Deng Y, Chen H, Yin X, Yang Y, Tan W. Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice. Adv Virol. 2015;160(10):2517–24.

41.

Saeedi A, Ghaemi A, Tabarraei A, Moradi A, Gorji A, Semnani S, Soleimanjahi H, Adli AH, Hosseini SY, Vakili MA. Enhanced cell immune responses to hepatitis C virus core by novel heterologous DNA prime/lambda nanoparticles boost in mice. Virus Genes. 2014;49(1):11–21.PubMedCrossRef

42.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, et al. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis. 2013;208(6):1008–19.PubMedPubMedCentralCrossRef

43.

Park SH, Yang SH, Lee CG, Youn JW, Chang J, Sung YC. Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine. 2003;21(31):4555–64.PubMedCrossRef

44.

Bao LD, Ren XH, Ma RL, Wang Y, Yuan HW, Lv HJ. Efficacy of Artemisia annua polysaccharides as an adjuvant to hepatitis C vaccination. Genet Mol Res: GMR. 2015;14(2):4957–65.PubMedCrossRef

45.

Yang Y, Kuang Y, Liu Y, Li W, Jiang Z, Xiao L, Li M. Immunogenicity of multiple-epitope antigen gene of HCV carried by novel biodegradable polymers. Comp Immunol Microbiol Infect Dis. 2011;34(1):65–72.PubMedCrossRef

46.

Sun W, Li Q, Zhu D, Feng J, Zhuang Z, Sun X, Xiao G, Duan Y. Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag. J Med Virol. 2015;87(12):2090–7.PubMedCrossRef

47.

Nam SH, Park JH, Kang JH, Kang SY, Kim JH, Kim SY, Ahn JI, Park KS, Chung HJ. Modulation of immune response induced by co-administration of DNA vaccine encoding HBV surface antigen and HCV envelope antigen in BALB/c mice. Arch Pharmacal Res. 2006;29(11):1042–8.CrossRef

48.

Jin J, Yang JY, Liu J, Kong YY, Wang Y, Li GD. DNA immunization with fusion genes encoding different regions of hepatitis C virus E2 fused to the gene for hepatitis B surface antigen elicits immune responses to both HCV and HBV. World J Gastroenterol. 2002;8(3):505–10.PubMedPubMedCentralCrossRef

49.

Memarnejadian A, Roohvand F. Fusion of HBsAg and prime/boosting augment Th1 and CTL responses to HCV polytope DNA vaccine. Cell Immunol. 2010;261(2):93–8.PubMedCrossRef

50.

Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B, Gowans EJ. A multiantigenic DNA vaccine that induces broad hepatitis C virus-specific T-cell responses in mice. J Virol. 2015;89(15):7991–8002.PubMedPubMedCentralCrossRef

51.

Shrestha AC, Wijesundara DK, Masavuli MG, Mekonnen ZA, Gowans EJ, Grubor-Bauk B. Cytolytic perforin as an adjuvant to enhance the immunogenicity of DNA vaccines. Vaccines. 2019;7(2):38.PubMedCentralCrossRef

52.

Gummow J, Masavuli MG, Mekonnen ZA, Li Y, Wijesundara DK, Shrestha AC, Voskoboinik I, Gowans EJ, Grubor-Bauk BJV. Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. 2020;8(1):53.

53.

Chen H, Gao N, Wu J, Zheng X, Li J, Fan D, An J. Variable effects of the co-administration of a GM-CSF-expressing plasmid on the immune response to flavivirus DNA vaccines in mice. Immunol Lett. 2015;162(1):140–8.CrossRef

54.

Encke J, Bernardin J, Geib J, Barbakadze G, Bujdoso T, Stremmel W. Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. World J Gastroenterol. 2006;12(44):7118–25.PubMedPubMedCentralCrossRef

55.

Hartoonian C, Sepehrizadeh Z, Tabatabai Yazdi M, Jang YS, Langroudi L, Amir Kalvanagh P, Negahdari B, Karami A, Ebtekar M, Azadmanesh K: Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization. Hepatitis monthly 2014, 14(3):e14611.

56.

Pouriayevali MH, Bamdad T, Sadat SM, Sadeghi SA, Sabahi F, Mahdavi M, Aghasadeghi MRJIl: Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. 2019, 71(10):1645–1652.

57.

Han JW, Sung PS, Hong SH, Lee H, Koh JY, Lee H, White S, Maslow JN, Weiner DB, Park SH, et al. IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. J Hepatol. 2020;73(1):72–83.PubMedCrossRef

58.

Sominskaya I, Alekseeva E, Skrastina D, Mokhonov V, Starodubova E, Jansons J, Levi M, Prilipov A, Kozlovska T, Smirnov V, et al. Signal sequences modulate the immunogenic performance of human hepatitis C virus E2 gene. Mol Immunol. 2006;43(12):1941–52.PubMedCrossRef

59.

Yu H, Babiuk LA. van Drunen Littel-van den Hurk S: Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol. 2004;85(Pt 6):1533–43.PubMedCrossRef

60.

Masavuli MG, Wijesundara DK, Underwood A, Christiansen D, Earnest-Silveira L, Bull R, Torresi J. Gowans EJ. Grubor-Bauk BJFiI: A hepatitis C virus DNA vaccine encoding a secreted, oligomerized form of envelope proteins is highly immunogenic and elicits neutralizing antibodies in vaccinated mice. 2019;10:1145.

61.

Ren Y, Min YQ, Liu M, Chi L, Zhao P, Zhang XL. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. Biochem Biophys Acta. 2015;1860:1764.PubMedCrossRef

62.

Liu M, Chen H, Luo F, Li P, Pan Q, Xia B, Qi Z, Ho WZ, Zhang XL. Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine. 2007;25(36):6572–80.PubMedCrossRef

63.

Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, Zhang X-L. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine. 2007;25(8):1544–51.PubMedCrossRef

64.

Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–88.PubMedPubMedCentralCrossRef

65.

Silva CL, Bonato VLD, dos Santos-Júnior RR, Zárate-Bladés CR, Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev Vaccines. 2009;8(2):239–52.PubMedCrossRef

66.

Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153–64.PubMedCrossRef

67.

Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019;10:594.PubMedPubMedCentralCrossRef

68.

Swadling L, Capone S, Antrobus Richard D, Brown A, Richardson R, Newell Evan W, Halliday J, Kelly C, Bowen D, Fergusson J, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Transl Med. 2014;6(261):153–261.CrossRef

69.

Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol. 2021;74(1):220–9.PubMedCrossRef

70.

Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016;41:18–22.PubMedCrossRef

71.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020;384(5):403–16.PubMedCrossRef

72.

Sharifnia Z, Bandehpour M, Kazemi B, Zarghami N. Design and development of modified mRNA encoding core antigen of hepatitis C virus: a possible application in vaccine production. Iran Biomed J. 2019;23(1):57–67.PubMedPubMedCentralCrossRef

73.

Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci. 2020;27(1):78.PubMedPubMedCentralCrossRef

74.

Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WO, Forman M, Thomas E, Thornton K. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384(6):541–9.PubMedPubMedCentralCrossRef

75.

Lee H, Jeong M, Oh J, Cho Y, Shen X, Stone J, Yan J, Rothkopf Z, Khan AS, Cho BM, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. Sci Rep. 2017;7(1):43531.PubMedPubMedCentralCrossRef

76.

Ahlen G, Holmstrom F, Gibbs A, Alheim M, Frelin L. Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination. Gene Ther. 2014;21(8):739–50.PubMedPubMedCentralCrossRef

77.

Gorzin Z, Gorzin AA, Tabarraei A, Behnampour N, Irani S, Ghaemi A. Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice. Iran Biomed J. 2014;18(1):1–7.PubMedPubMedCentral

78.

Wada T, Kohara M, Yasutomi Y. DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model. Vaccine. 2013;31(50):5968–74.PubMedCrossRef

79.

Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, Broderick KE, Chen M, Ahlén G, Frelin L. A synthetic codon-optimized hepatitis c virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T Cell responses in wild-type and NS5A-transgenic mice. J Immunol. 2013;190(3):1113–24.PubMedCrossRef

80.

Park SH, Song MY, Nam HJ, Im SJ, Sung YC. Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus Monkeys. Immune network. 2010;10(6):198–205.PubMedPubMedCentralCrossRef

81.

Masalova OV, Lesnova EI, Grabovetskii VV, Smirnova OA, Ulanova TI, Burkov AN, Ivanov AV, Zaberezhnyi AD, Ataullakhanov RI, Kushch AA. DNA immunization with a plasmid containing gene of hepatitis C virus protein 5A (NS5A) induces the effective cellular immune response. Mol Biol. 2010;44(2):275–83.CrossRef

82.

Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine. 2008;26(49):6225–31.PubMedPubMedCentralCrossRef

83.

Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12(2):190–7.PubMedCrossRef

84.

Li YP, Kang HN, Babiuk LA, Liu Q. Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World J Gastroenterol. 2006;12(44):7126–35.PubMedPubMedCentralCrossRef

85.

Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis. 2005;192(12):2112–6.PubMedCrossRef

86.

Zhu LX, Liu J, Ye Y, Xie YH, Kong YY, Li GD, Wang Y. A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol. 2004;10(17):2488–92.PubMedPubMedCentralCrossRef

87.

Ou-Yang P, Hwang LH, Tao MH, Chiang BL, Chen DS. Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J Med Virol. 2002;66(3):320–8.PubMedCrossRef

88.

Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine. 2002;20(27–28):3263–71.PubMedCrossRef

Title: Hepatitis C virus DNA vaccines: a systematic review
Authors: Ali Shayeghpour
Roya Kianfar
Parastoo Hosseini
Mehdi Ajorloo
Sepehr Aghajanian
Mojtaba Hedayat Yaghoobi
Tayebeh Hashempour
Sayed-Hamidreza Mozhgani
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Hepatitis C
Published in: Virology Journal / Issue 1/2021
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-021-01716-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Molecular-genetic characterization of human parvovirus B19 prevalent in Kerala State, India

High-risk human papillomavirus detection in self-collected vaginal samples compared with healthcare worker collected cervical samples among women attending gynecology clinics at a tertiary hospital in Pretoria, South Africa

Caveolin-1 is involved in encephalomyocarditis virus replication in BHK-21 cells

Evaluation of patients with COVID-19 diagnosis for chronic diseases

Evolutionary trajectory of SARS-CoV-2 and emerging variants

Genome sequences of human cytomegalovirus strain TB40/E variants propagated in fibroblasts and epithelial cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials